<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PIM serine/threonine kinases are overexpressed, translocated, or amplified in multiple B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types </plain></SENT>
<SENT sid="1" pm="."><plain>We have explored the frequency and relevance of PIM expression in different B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> types and investigated whether PIM inhibition could be a rational therapeutic approach </plain></SENT>
<SENT sid="2" pm="."><plain>Increased expression of PIM2 was detected in subsets of mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DLBLC), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-mucosa-associated lymphoid tissue type, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, and nodal marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cases </plain></SENT>
<SENT sid="3" pm="."><plain>Increased PIM2 protein expression was associated with an aggressive clinical course in activated B-like-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Pharmacologic and genetic inhibition of PIM2 revealed p4E-BP1(Thr37/46) and p4E-BP1(Ser65) as molecular biomarkers characteristic of PIM2 activity and indicated the involvement of PIM2 kinase in regulating mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi> complex 1 </plain></SENT>
<SENT sid="5" pm="."><plain>The simultaneous genetic inhibition of <z:hpo ids='HP_0000001'>all</z:hpo> 3 PIM kinases induced changes in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, we show that PIM2 kinase inhibition is a rational approach in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> treatment, identify appropriate biomarkers for pharmacodynamic studies, and provide a new marker for patient stratification </plain></SENT>
</text></document>